Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -135.62% is in line with its 5-year average of -127.51%, near the high end of its 5-year range (-661.54%–-13.83%).
As of the fiscal period ended Tuesday, June 30, 2026. 65.03% above its 12-month average of -387.80%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -135.62%.
RETURN ON EQUITY (ROE)
-135.62%
RETURN ON EQUITY (ROE) AVG TTM
-387.80%
RETURN ON EQUITY (ROE) AVG 3Y
-279.51%
RETURN ON EQUITY (ROE) AVG 5Y
-127.51%
RETURN ON EQUITY (ROE) AVG 10Y
-135.93%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+65.03%
CURRENT VS 3Y AVG
+51.48%
CURRENT VS 5Y AVG
-6.36%
CURRENT VS 10Y AVG
+0.23%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 621 covered companies
CURRENT VS SECTOR MEDIAN
-237.36%
vs the sector median at left
Indaptus Therapeutics, Inc.
Market Cap
$285.37M
Return on Equity (ROE)
-135.62%
TTM Avg
-387.80%
3Y Avg
-279.51%
5Y Avg
-127.51%
Market Cap
$284.21M
Return on Equity (ROE)
-27.36%
TTM Avg
-12.73%
3Y Avg
-30.52%
5Y Avg
-39.12%
Market Cap
$288.40M
Return on Equity (ROE)
-49.11%
TTM Avg
-50.02%
3Y Avg
-153.47%
5Y Avg
-149.41%
Market Cap
$289.76M
Return on Equity (ROE)
-16.18%
TTM Avg
-23.55%
3Y Avg
59.17%
5Y Avg
22.66%
Market Cap
$280.29M
Return on Equity (ROE)
-21.41%
TTM Avg
-11.72%
3Y Avg
-50.56%
5Y Avg
-98.46%
Market Cap
$289.63M
Return on Equity (ROE)
-56.36%
TTM Avg
-35.98%
3Y Avg
25430.43%
5Y Avg
20391.58%
Market Cap
$277.99M
Return on Equity (ROE)
-82.12%
TTM Avg
-62.12%
3Y Avg
-56.53%
5Y Avg
-50.41%
Market Cap
$274.62M
Return on Equity (ROE)
-4.68%
TTM Avg
-68.17%
3Y Avg
-57.88%
5Y Avg
-49.64%
Market Cap
$296.13M
Return on Equity (ROE)
-135.50%
TTM Avg
-129.54%
3Y Avg
-84.04%
5Y Avg
-77.00%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | $285.37M | -135.62% | -387.80% | -279.51% | -127.51% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $284.21M | -27.36% | -12.73% | -30.52% | -39.12% |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.40M | -49.11% | -50.02% | -153.47% | -149.41% |
| Standard BioTools Inc. (LAB)vs › | $289.76M | -16.18% | -23.55% | 59.17% | 22.66% |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | -21.41% | -11.72% | -50.56% | -98.46% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $289.63M | -56.36% | -35.98% | 25430.43% | 20391.58% |
| Fate Therapeutics, Inc. (FATE)vs › | $277.99M | -82.12% | -62.12% | -56.53% | -50.41% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | -4.68% | -68.17% | -57.88% | -49.64% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $296.13M | -135.50% | -129.54% | -84.04% | -77.00% |
| Benitec Biopharma Inc. (BNTC)vs › | $301.43M | -25.73% | -32.35% | -2448.72% | -1749.34% |
ROE
-135.6%
ROA
-128.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -135.62% |
| 2025-12-31 | -661.54% |
| 2025-09-30 | -366.23% |
| 2025-03-31 | -562.47% |
| 2024-12-31 | -380.80% |
| 2024-09-30 | -248.09% |
| 2024-06-30 | -255.38% |
| 2024-03-31 | -160.00% |
| 2023-12-31 | -127.71% |
| 2023-09-30 | -98.32% |
| 2023-06-30 | -78.50% |
| 2023-03-31 | -71.80% |
| 2022-12-31 | -58.15% |
| 2022-09-30 | -50.36% |
| 2022-06-30 | -45.33% |
| 2022-03-31 | -31.37% |
| 2021-12-31 | -21.48% |
| 2021-09-30 | -13.83% |
| 2021-06-30 | -24.69% |
| 2020-09-30 | -64.19% |
| 2020-06-30 | -188.15% |
| 2020-03-31 | -263.72% |
| 2019-12-31 | -412.65% |
| 2019-09-30 | -306.78% |
| 2019-06-30 | -120.90% |
| 2019-03-31 | -98.60% |
| 2018-12-31 | -81.32% |
| 2018-09-30 | -63.01% |
| 2018-06-30 | -53.82% |
| 2018-03-31 | -72.01% |
| 2017-12-31 | -49.16% |
| 2015-12-31 | -20.14% |
